A novel Phase 2 double-blind randomized controlled clinical trial to evaluate the efficacy of centrally acting non-toxic ACE inhibition in cognitive impairment associated with SLE

Brief description of study

This research study is being done to test the effects of centrally-acting ACE inhibitor, named lisinopril, on resting metabolism in the brain and on cognitive function in lupus patients with elevated resting metabolism on a screening FDG-PET scan performed prior to study enrollment. The researchers will see if Lisinopril will decrease resting metabolism in the brain and improve cognitive function (memory and concentration).

Clinical Study Identifier: s19-01858
ClinicalTrials.gov Identifier: NCT04486118

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.